JP2019531764A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531764A5
JP2019531764A5 JP2019537049A JP2019537049A JP2019531764A5 JP 2019531764 A5 JP2019531764 A5 JP 2019531764A5 JP 2019537049 A JP2019537049 A JP 2019537049A JP 2019537049 A JP2019537049 A JP 2019537049A JP 2019531764 A5 JP2019531764 A5 JP 2019531764A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
binding domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019537049A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531764A (ja
JP7224289B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/052808 external-priority patent/WO2018057802A1/en
Publication of JP2019531764A publication Critical patent/JP2019531764A/ja
Publication of JP2019531764A5 publication Critical patent/JP2019531764A5/ja
Priority to JP2023016697A priority Critical patent/JP2023058573A/ja
Application granted granted Critical
Publication of JP7224289B2 publication Critical patent/JP7224289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019537049A 2016-09-21 2017-09-21 Cd123結合タンパク質並びに関連する組成物及び方法 Active JP7224289B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023016697A JP2023058573A (ja) 2016-09-21 2023-02-07 Cd123結合タンパク質並びに関連する組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662397736P 2016-09-21 2016-09-21
US62/397,736 2016-09-21
US201762466192P 2017-03-02 2017-03-02
US62/466,192 2017-03-02
PCT/US2017/052808 WO2018057802A1 (en) 2016-09-21 2017-09-21 Cd123 binding proteins and related compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023016697A Division JP2023058573A (ja) 2016-09-21 2023-02-07 Cd123結合タンパク質並びに関連する組成物及び方法

Publications (3)

Publication Number Publication Date
JP2019531764A JP2019531764A (ja) 2019-11-07
JP2019531764A5 true JP2019531764A5 (https=) 2020-12-17
JP7224289B2 JP7224289B2 (ja) 2023-02-17

Family

ID=61690646

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019537049A Active JP7224289B2 (ja) 2016-09-21 2017-09-21 Cd123結合タンパク質並びに関連する組成物及び方法
JP2023016697A Pending JP2023058573A (ja) 2016-09-21 2023-02-07 Cd123結合タンパク質並びに関連する組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023016697A Pending JP2023058573A (ja) 2016-09-21 2023-02-07 Cd123結合タンパク質並びに関連する組成物及び方法

Country Status (17)

Country Link
US (4) US11242400B2 (https=)
EP (1) EP3515491A4 (https=)
JP (2) JP7224289B2 (https=)
KR (1) KR102559732B1 (https=)
CN (1) CN109952112B (https=)
AU (1) AU2017331256B2 (https=)
BR (1) BR112019005333A2 (https=)
CA (1) CA3037688A1 (https=)
CO (1) CO2019003951A2 (https=)
IL (1) IL265484B2 (https=)
MX (2) MX2019003225A (https=)
MY (1) MY194290A (https=)
PH (1) PH12019500609B1 (https=)
SG (1) SG10202102846SA (https=)
UA (1) UA127450C2 (https=)
WO (1) WO2018057802A1 (https=)
ZA (1) ZA201902323B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL260021B (en) 2015-12-14 2022-09-01 Macrogenics Inc Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
CN109952112B (zh) 2016-09-21 2024-09-06 阿帕特夫研究和发展有限公司 Cd123结合蛋白和相关的组合物和方法
JP2022532868A (ja) * 2019-05-04 2022-07-20 インヒブルクス インコーポレイテッド Cd123結合性ポリペプチド及びその使用
EP3753954A1 (en) * 2019-06-21 2020-12-23 Université de Franche-Comté Anti-cd123 antibodies, anti-cd123 chimeric antigen receptors and anti-cd123 chimeric antigen receptors t cells
US20220242962A1 (en) * 2019-08-12 2022-08-04 Aptevo Research And Development Llc 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
CN110804096B (zh) * 2019-11-21 2021-07-06 深圳普瑞金生物药业有限公司 Cd123单域抗体、核苷酸序列、表达载体及试剂盒
BR112022013730A2 (pt) * 2020-01-13 2022-10-11 Aptevo Res & Development Llc Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas
WO2021146328A1 (en) * 2020-01-13 2021-07-22 Aptevo Research And Development Llc Formulations for protein therapeutics
CN111349163B (zh) 2020-02-05 2024-07-16 北京智仁美博生物科技有限公司 针对cd123的单克隆抗体
US20230273126A1 (en) * 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CN111732635B (zh) * 2020-06-22 2022-03-22 中国医学科学院基础医学研究所 与cd123蛋白特异性结合的多肽、多肽复合物、共递送系统及其制备方法与应用
EP4232159A1 (en) * 2020-10-23 2023-08-30 Icahn School of Medicine at Mount Sinai Sars-cov-2 antibodies and uses thereof
IL303328A (en) * 2020-12-01 2023-07-01 Aptevo Res & Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
US20240076392A1 (en) * 2021-02-17 2024-03-07 Igm Biosciences, Inc. Anti-cd123 binding molecules and uses thereof
EP4341291A1 (en) * 2021-05-21 2024-03-27 Aptevo Research and Development LLC Dosing regimens for protein therapeutics
CN116162148B (zh) * 2021-11-24 2025-09-09 中山光度生物医药有限公司 多特异性配体结合分子及其应用
CN116836282B (zh) * 2023-02-13 2024-03-29 北京艺妙神州医药科技有限公司 抗体、嵌合抗原受体及其用途
CN117660325B (zh) * 2024-01-31 2024-04-19 苏州科为康生物医药科技有限公司 一种制备脐带血msc的培养基及其方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
US20050009743A1 (en) 2001-07-26 2005-01-13 Sundquist Wesley I In vitro assays for inhibitors of hiv capsid conformational changes and for hiv capsid formation
JP2006508638A (ja) * 2002-05-22 2006-03-16 エスバテック・アーゲー 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
WO2005058251A2 (en) 2003-12-15 2005-06-30 Dendreon Corporation Hla-dr-specific antibodies, compositions and methods
AU2006210660B2 (en) 2005-02-01 2011-12-01 Morphosys Ag Libraries and methods for isolating antibodies
JP2008539785A (ja) * 2005-05-16 2008-11-20 モルフォテック、インク. 所望の表現型を示す細胞を選択するために制御されたベクター
WO2007009064A2 (en) 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
US7949480B2 (en) 2006-06-14 2011-05-24 Simphotek, Inc. Method for determining an interaction between an electromagnetic radiation and a material
DK2066694T3 (en) * 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
EP2187971A2 (en) 2007-08-01 2010-05-26 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services A fold-back diabody diphtheria toxin immunotoxin and methods of use
US20110293619A1 (en) * 2008-10-01 2011-12-01 Micromet Ag CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
JP5694923B2 (ja) * 2009-04-27 2015-04-01 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗IL−3Rα抗体
CA2771336C (en) 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
NZ604510A (en) * 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
EP2637692A4 (en) 2010-11-12 2014-09-10 Scott & White Healthcare ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
JP6509724B2 (ja) * 2012-04-20 2019-05-08 アプティーボ リサーチ アンド デベロップメント エルエルシー Cd3結合ポリペプチド
PT2850106T (pt) * 2012-05-18 2022-07-18 Aptevo Res & Development Llc Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3
WO2014143807A2 (en) * 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
MA40609B1 (fr) * 2014-09-05 2020-05-29 Janssen Pharmaceutica Nv Agents de liaison cd123 et leurs utilisations
US10259887B2 (en) * 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
US20180022819A1 (en) 2015-02-11 2018-01-25 Aptevo Research And Development Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
WO2017053469A2 (en) * 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2017210443A1 (en) 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd123 and cd3
CN109952112B (zh) 2016-09-21 2024-09-06 阿帕特夫研究和发展有限公司 Cd123结合蛋白和相关的组合物和方法
WO2021146328A1 (en) 2020-01-13 2021-07-22 Aptevo Research And Development Llc Formulations for protein therapeutics
BR112022013730A2 (pt) 2020-01-13 2022-10-11 Aptevo Res & Development Llc Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas

Similar Documents

Publication Publication Date Title
JP2019531764A5 (https=)
JP2023058573A5 (https=)
JP2021524244A5 (https=)
JP2019110906A5 (https=)
JP2015533853A5 (https=)
JP2018531000A5 (https=)
IL276830B1 (en) Anti-claudin 18.2 antibodies and their uses
JP2016505556A5 (https=)
JP2021514664A5 (https=)
JP2020501531A5 (https=)
JP2017149720A5 (https=)
JP2018510617A5 (https=)
JP2017535257A5 (https=)
JP2018503380A5 (https=)
JP2017506067A5 (https=)
HK1215035A1 (zh) 人源化抗cd134(ox40)抗體及其應用
JP2016512223A5 (https=)
JP2018513149A5 (https=)
RU2014106671A (ru) Варианты гуманизированных иммуномодулирующих моноклональных антител
JP2013545738A5 (https=)
JP2020530770A5 (https=)
JP2024504471A5 (https=)
IL272103B1 (en) Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods of treating cancer
JP2020502147A5 (https=)
JP2022527081A5 (https=)